TY - JOUR
T1 - Blood and bone marrow transplantation for acute myeloid leukemia
AU - Villela, Luis M.
AU - Bolaños-Meade, Javier
N1 - Funding Information:
42. Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addi-tion of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351:700-8.
Funding Information:
25. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999; 107:69-79.
Funding Information:
24. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 1998; 92:2322-33.
PY - 2009
Y1 - 2009
N2 - Bone marrow transplantation is the treatment of choice for some patients with acute myeloid leukemia and myelodysplastic syndrome (MDS). Patients with high-risk disease, such as those with MDS, in second (or subsequent) complete remission or those with poor-risk cytogenetics will benefit the most from this approach. With current transplantation techniques, outcomes have improved over recent years. Although relapse and graft-versus-host disease still are important problems faced by these patients, novel approaches have been developed to decrease the risk of complications, with excellent results.
AB - Bone marrow transplantation is the treatment of choice for some patients with acute myeloid leukemia and myelodysplastic syndrome (MDS). Patients with high-risk disease, such as those with MDS, in second (or subsequent) complete remission or those with poor-risk cytogenetics will benefit the most from this approach. With current transplantation techniques, outcomes have improved over recent years. Although relapse and graft-versus-host disease still are important problems faced by these patients, novel approaches have been developed to decrease the risk of complications, with excellent results.
KW - Donor lymphocyte infusion
KW - Graft-versus-host disease
KW - Myelodysplastic syndrome
KW - Promyelocytic leukemia
UR - http://www.scopus.com/inward/record.url?scp=70350333359&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350333359&partnerID=8YFLogxK
U2 - 10.3816/CLK.2009.n.009
DO - 10.3816/CLK.2009.n.009
M3 - Review article
AN - SCOPUS:70350333359
SN - 1931-6925
VL - 3
SP - E11-E21
JO - Clinical Leukemia
JF - Clinical Leukemia
IS - 2
ER -